Pirarubicin

This image is provided by the National Library of Medicine.

WikiDoc Resources for Pirarubicin
Articles
Most recent articles on Pirarubicin Most cited articles on Pirarubicin Review articles on Pirarubicin Articles on Pirarubicin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Pirarubicin Images of Pirarubicin Photos of Pirarubicin Podcasts & MP3s on Pirarubicin Videos on Pirarubicin
Evidence Based Medicine
Cochrane Collaboration on Pirarubicin Bandolier on Pirarubicin TRIP on Pirarubicin
Clinical Trials
Ongoing Trials on Pirarubicin at Clinical Trials.gov Trial results on Pirarubicin Clinical Trials on Pirarubicin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Pirarubicin NICE Guidance on Pirarubicin NHS PRODIGY Guidance FDA on Pirarubicin CDC on Pirarubicin
Books
Books on Pirarubicin
News
Pirarubicin in the news Be alerted to news on Pirarubicin News trends on Pirarubicin
Commentary
Blogs on Pirarubicin
Definitions
Definitions of Pirarubicin
Patient Resources / Community
Patient resources on Pirarubicin Discussion groups on Pirarubicin Patient Handouts on Pirarubicin Directions to Hospitals Treating Pirarubicin Risk calculators and risk factors for Pirarubicin
Healthcare Provider Resources
Symptoms of Pirarubicin Causes & Risk Factors for Pirarubicin Diagnostic studies for Pirarubicin Treatment of Pirarubicin
Continuing Medical Education (CME)
CME Programs on Pirarubicin
International
Pirarubicin en Espanol Pirarubicin en Francais
Business
Pirarubicin in the Marketplace Patents on Pirarubicin
Experimental / Informatics
List of terms related to Pirarubicin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Pirarubicin (INN) is an anthracycline drug. An analogue of the anthracycline antineoplastic antibiotic doxorubicin. Pirarubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. This agent is less cardiotoxic than doxorubicin and exhibits activity against some doxorubicin-resistant cell lines.